SGLT2 Inhibitor for Cardiac Protection in a Patient With Osimertinib-Responsive Advanced EGFR-Positive Lung Cancer
Aditya V Belamkar, Marwan Mounayar, Suparna C Clasen · 2024
Read SGLT2 Inhibitor for Cardiac Protection in a Patient With Osimertinib-Responsive Advanced EGFR-Positive Lung Cancer by Aditya V Belamkar, Marwan Mounayar, Suparna C Clasen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11646913.txt.
Description
Belamkar, Mounayar, and Clasen report heart protection during lung cancer therapy, in work from twenty twenty-four. Their patient was a man aged eighty-five with advanced lung cancer carrying an EGFR mutation. The targeted drug osimertinib shrank the cancer but appeared to weaken his heart.
After one month he arrived in heart failure with rhythm problems and kidney injury. The drug was held, heart drugs were started, and heart function recovered. When the cancer drug resumed, function fell again, supporting a drug effect. Adding an SGLT2 inhibitor, a heart protective diabetes drug class, is the reported strategy to keep both treatments going.
Catalog record
| CREATOR | Aditya V Belamkar, Marwan Mounayar, Suparna C Clasen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |